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INTRODUCTION:  We  present  the case  of  a patient  with  dilatative  cardiomyopathy  waiting  for  heart  trans-
plantation  with  pleural  effusion  to  be subjected  to pleural  biopsy,  treated  with  preoperative  infusion  of
levosimendan  to  improve  heart performances.
PRESENTATION  OF  CASE:  A 56-year-old  man  (BMI  22,49)  with  dilatative  cardiomyopathy  (EF  18%) pre-
sented  right  pleural  effusion.  The  levosimendan  treatment  protocol  consisted  of 24 h continuous  infusion
(0,1  ug/kg/min),  without  bolus.  The  patient  was  under  continuous  hemodynamic  monitoring  prior,  dur-
ing  and  after  levosimendan  administration.  The  surgery  for pleural  biopsy  was  performed  with  uniportal
Video Assisted  Thoracoscopic  approach  (VATS).
DISCUSSION:  A  signiﬁcant  increase  of Cardiac  Index  (CI)  and  Stroke  Volume  Index  (SVI)  were  observed  athoracic surgery 4  h  after  infusion  initiation  and  was  sustained  during  the next  24  h  after  the  end  of infusion.  Levosimendan
administration  was  safe.
CONCLUSION:  In this  case the  prophylactic  preoperative  levosimendan  administration  is safe  and  effec-
tive in cardiac  failure  patient undergoing  thoracic  surgery,  but prophylactic  preoperative  levosimendan
treatment  in these  patients  merits  further  study.
©  2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Heart failure is an important risk factor for mortality and
ardiovascular complications after non cardiac surgery [1,2]. Lev-
simendan, in contrast to other positve inotropic agents, has the
dvantage to improve cardiac performance and hemodynamics in
F patients without increasing myocardial oxygen consumption or
howing any proarrhythmic effects [3].
The use of levosimendan for perioperative optimization of
atients undergoing cardiac surgery has been reported in several
tudies [4,5], however it has not been thouroughly evaluated in
ardiac failure patients undergoing non cardiac surgery.We present the case of a patient with dilatative cardiomyopa-
hy waiting for heart transplantation with pleural effusion to be
∗ Corresponding author at: Anesthesia and Intensive Care, AORN dei Colli Vincenzo
onaldi Hospital, Traversa Galliano 9, 80021 Afragola, Naples, Italy.
E-mail addresses: marco-rispoli@hotmail.it (M.  Rispoli),
ario.mattiacci@libero.it (D.M. Mattiacci), mauro97@libero.it (S. Buono).
ttp://dx.doi.org/10.1016/j.ijscr.2016.08.003
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/).subjected to VATS for pleural biopsy, treated with preoperative
infusion of levosimendan to improve heart performance.
Consent was obtained from the patient.
2. Presentation of Case
A 56-year-old man  (height 170 cm,  weight 65 kg, BMI 22,49)
with dilatative cardiomyopathy (EF 18%) presented right pleural
effusion. Cytological examination of pleural ﬂuid was not diag-
nostic to exclude a malignancy therefore needed surgical pleural
biopsies to get diagnosis in order to be put in list for transplantation.
The patient previously underwent surgery for aortic and mitral
valve replacement and implanted a pacemaker (INCEPTA CRT-D
P162).
The patient was admitted to our PACU the day before the surgery
for levosimendan administration.The levosimendan treatment protocol consisted of 24 h continu-
ous infusion (0,1 ug/kg/min), without bolus. The patient was  under
continuous hemodynamic monitoring prior, during and after lev-
osimendan administration.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 2. Changes in Stroke Volume Index.Fig. 1. Changes in Cardiac Index.
The monitoring included continuous heart rate monitoring
ia electrocardiogram, arterial blood pressure via femoral artery
atheter, urine output, pulse oximetry, PVC throught venous
atheter in internal jugular vein, cardiac output (CO), cardiac index
CI), stroke volume index (SVI), central venous oxygen saturation
ScvO2) and oxygen delivery (DO2) via EV1000 (Edwards Life-
ciences). Blood tests were performed every 12 h and blood gas
nalysis every 4 h. Before levosimendan infusion CI was 1,9, SVI
as 28, ScvO2 was 48%. The surgery was performed at the end of
evosimendan treatment.
Intraoperative monitoring included continuous electrocardio-
ram, SpO2, blood pressure, bispectral index monitor (BIS), train
f four watch (TOF), INVOS 5100C cerebral somatic oximeter
Medtronic, Dublin, Ireland) to assess the cerebral oxygenation,
V1000 to asses emodinamic parameters. Midazolam premedi-
ation (0,03 mg/kg) was administere i.v. 10 min  before induction
f anesthesia. General anesthesia was induced with a target con-
rolled infusion of propofol/remifentanil and rocuronium bromide
0,6 mg/kg) and manteined with propofol/remifentanil and supple-
ental bolus of rocuronium accorded TOF values. A left DLT 39 Fr
Rusch, Durham, NC) was positioned and checked with FOB, the
ungs were mechanically ventilated with an oxygen-air mixture
FiO2 50%), the OLV was performed with CMV-AF 5 ml/Kg, RR for
tCO2 <40 mmHg, PEEP 5.
The surgery for pleural biopsy was performed with unipor-
al Video Assisted Thoracoscopic (VATS) approach at V intercostal
pace. The time of intervention was 70 min. One thoracic drainage
as placed at the end of surgery. Patient awake comfort full.
No complicances occured during anesthesia and hemodinamic
nd respiratory parameters were stables during surgery.
The monitoring was continued postoperatively in the PACU until
4 h post infusion.An evident increase of CI and SVI were observed
t 4 h after infusion initiation and was sustained during the next
4 h after the end of infusion (Fig. 1 and Fig. 2). Additionally, ScvO2
as increased at 4 h after infusion initiation and kept increasing
uring the 24 post infusion hours. (Fig. 3). Levosimendan showed
o harmfull effect on HR, SAP, DAP or MAP, administration was  safe,
o adverse drug reaction or complication occurred during follow
p.
Pleural biopsies reported histological evidence of chronic
leurisy.
. DiscussionA decreased preoperative EF has been associated with increased
ostoperative morbidity and mortality, while perioperative left
entricular dysfunction is one of the major predictors of postop-
rative cardiac complication [6].Fig. 3. Changes in Central Venous Oxygen Saturation.
During the last years an increasing number of patients with
high perioperative risk and decreased left ventricular function are
referred to cardiac and non cardiac surgery; heart failure is the
major cause of perioperative morbidity and mortality.
The effect of levosimendan as an inodilator are based on a triple
mechanism of action that provides positive inotropy equal or even
superior to any of the other commercially available inotropic agents
with a neutral effect on oxygen consumption and with precon-
ditioning, cardioprotective, antistunning and antischemic effects
[7–13].
Levosimendan produces signiﬁcant dose-dependent increases
in stroke volume and cardiac output and decreases in pulmonary
capillary wedge pressure, mean blood pressure, mean pulmonary
artery pressure, mean right atrial pressure ant total peripheral
resistance [14].
Clinical studies show that levosimendan effectively improves
general and pulmonary haemodynamics in patients undergoing
cardiac surgery, thereby reducing the need for inotropic agents and
mechanical circulatory support and additionally optimising renal
and hepatic function.
The unique inotropic and cardioprotective properties of levosi-
mendan can provide sustained effects for several days and can
thus help to reduce complications in the postoperative period
[4].
Tritapepe and collegues reported that short infusion of lev-
osimendan before the initiation of CABG results in higher
postoperative cardiac index and lower troponina concentration, in
signiﬁcant reductions in tracheal intubation time, length of ICU stay
and number of patients requiring inotropic support [15].
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In a randomized trial vs placebo, Levin and collegues evaluated
he effects of 23 h infusion preoperative levosimendan in high risk
atients with severe left ventriculardysfunction undergoing CABG
ith cardiopulmonarybypass (EF < 25%). Levosimendan group had
 lower incidence of complicated weaning from CPB, decresed mor-
ality and lower incidence of LCOS, lower requirement for inotropes
nd intra-aortic ballon pumps [16].
Taking into account these multiple but complementary mecha-
isms, levosimendan appears to be a suitable agent for preoperative
ptimization of cardiac functions in heart failure patients undergo-
ng major elective surgery [17,18], but has not been thoroughly
valuated in CF patients undergoing thoracic surgery.
We  evaluated the effects of prophylactic preoperative levosi-
endan administration in a CF patient undergoing thoracic surgery
n uniportal VATS in general anesthesia.
Considering that in case like this it is not unusual to have unilat-
ral effusion especially since the left chest/pleura was transversed
hrough previous operation and therefore adhesion formation in
he space would limit a visible effusion on the left, pleural biopsy
ould seem an overtreatment, but the transplant list required us to
ave the assurance about not being a malignant lesion, regardless
f clinical probability.
The high risk related to general anesthesia in not negligible, but
leuroscopy or thoracoscopy in local anesthesia allow surgeons to
ake samples in the more favorable area of the pleura with random
iopsies. In our case we need to get that speciﬁc effusion, in the
orsal apex area of the lung, so lung collapse was needed.
Hemodynamic monitoring was performed with EV 1000
Edwards Lifesciences).
The EV1000 clinical platform presents the physiologic status
f the patient in an intuitive and meaningful way and offers you
calability and adaptability for both the OR and ICU.
With EV 1000 we have monitored hemodynamic optimization.
ardiac output, CI, SVI measured continuously can be used (in com-
ination with SaO2 and hemoglobin) to monitor and optimize DO2
ith ﬂuid and inotropic agents [19,20].
In our CF patient levosimendan increases CI, SVI and ScvO2. Lev-
simendan administration in a 24 h continuos infusion resulted
n beneﬁcal improvement of patient’s hemodynamics and cardiac
erformance, effects that were sustained for at least another 24 h
nd, in the case of EF, 7 days. No difference was noted between CI,
VI, Do2 values at the end of levosimendan infusion and the post-
perative values. The ﬁnding that this optimization was substained
onstantly throughout the intra and postoperative period, when the
urgical stress is greater.
. Conclusion
In conclusion, in our experience the prophylactic preoperative
evosimendan administration is safe and effective in cardiac failure
atient undergoing thoracic surgery. Levosimendan could be safely
dministrered to CF patients undergoing thoracic surgery, but pro-
hylactic preoperative levosimendan treatment in these patients
erits further study.
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